Vic biotechnology researcher Dr David Ackerley has been awarded $388,000 in funding from the Cancer Society for research into bacterial enzymes.
The project has the potential for use in the delivery of chemotherapeutic drugs and will build on the work of researchers at the Auckland Cancer Society Research Centre who this year developed and began trialing the chemotherapeutic “smart-drug” PR-104.
Ackerley’s research combines internationally recognised work in microbiology, molecular biology, and medicinal chemistry.
He said the technology will potentially enable more effective chemotherapeutic treatments that have diminished side-effects in the human body.
Laura McQuillan and NZPA
[ssba]